GlassScriptPhysician profile
Peter Wolfgang Ledwin Bean
NPI 1336730654
$5,190.58
in general payments reported to CMS, 2019-2025
25 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,584 · 2023: $2,434 · 2024: $1,071 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $807.85 | 2022-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $549.01 | 2022-2023 | Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $444.84 | 2022-2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $430.88 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $333.05 | 2022-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $286.38 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $283.71 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $283.30 | 2022-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $277.90 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $275.23 | 2022-2023 | Ingrezza |
| Uswm, LLC | $269.52 | 2022-2023 | Zimhi, Lucemyra |
| Indivior INC. | $241.09 | 2022-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $105.78 | 2022 | |
| Bausch Health US, LLC | $88.97 | 2022-2023 | Wellbutrin, Aplenzin |
| Idorsia Pharmaceuticals US INC | $85.33 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $75.50 | 2022-2023 | Loreev Xr |
| Merck Sharp & Dohme LLC | $71.00 | 2022-2023 | Belsomra |
| Lundbeck LLC | $66.17 | 2022-2023 | Rexulti |
| Noven Therapeutics, LLC | $60.47 | 2022-2023 | Xelstrym, Secuado |
| Braeburn INC. | $46.16 | 2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $40.53 | 2022 | |
| Orexo US, INC. | $19.29 | 2024 | Zubsolv |
| Corium, LLC | $18.36 | 2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $15.95 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.